RTP Mobile Logo
Interactive Tumor Panel: Clinical Investigators Discuss Available Research Shaping the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer
Released June 2018

Proceedings from a CME symposium held at the 2018 AACR Annual Meeting. Featuring perspectives from Drs Hossein Borghaei, Leena Gandhi, Matthew D Hellmann, Roy S Herbst, Corey J Langer and audience engagement liaison, Dr Matthew Gubens. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, surgeons, radiation oncologists, oncology nurses and other healthcare professionals involved in basic, translational and clinical cancer research or treatment.

    The past several years have seen an explosion in the emergence of new therapies that leverage the natural ability of the human body to attack and treat cancer. Known as cancer immunotherapies, these treatments are generating excitement all over the world as they have reshaped the management of lung cancer in previously unimagined ways. That being said, a number of controversies and questions remain with regard to the current application of these agents in clinical practice.

    These video proceedings from a CME symposium held during the 2018 AACR Annual Meeting feature discussions with leading lung cancer researchers regarding actual patient cases and related clinical research findings. By providing information on important developments, this activity will assist medical oncologists and other healthcare professionals to address existing management uncertainties and determine the current and future roles of immune checkpoint inhibitors in this disease.


    • Analyze the biologic basis for the development of immune checkpoint inhibitors designed to boost an individual’s immune response to combat cancer.
    • Appreciate available Phase III data documenting the benefit of sequential anti-PD-L1 therapy after the completion of chemoradiation therapy for Stage III non-small cell lung cancer (NSCLC), and consider the role of durvalumab for appropriate patients.
    • Recognize available and emerging research information validating the utility of diagnostic assays designed to measure PD-L1 status, assess which testing platforms should be used and appropriately employ the results to individualize first- and later-line therapy for patients with metastatic NSCLC based on their potential response (or lack thereof) to an immune checkpoint inhibitor.
    • Compare and contrast the mechanisms of action, efficacy and safety/toxicity of approved and investigational anti-PD-1/PD-L1 antibodies for the treatment of NSCLC to determine the current and/or potential utility of these agents in clinical practice.
    • Review published research documenting the safety and efficacy of anti-PD-1 antibodies used as monotherapy or in combination with chemotherapy for patients with newly diagnosed metastatic NSCLC.
    • Describe the biologic rationale for and current clinical role of anti-PD-1/PD-L1 antibodies alone or in combination with other therapeutic approaches for small cell lung cancer (SCLC).
    • Describe ongoing research to assist in the identification of additional biomarkers, tumor characteristics or other clinical features that are indicative of response to immune checkpoint inhibitors in patients with lung cancer.
    • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic and systemic therapies for NSCLC and SCLC, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Hossein Borghaei, DO, MS
    Associate Professor
    Chief, Thoracic Medical Oncology
    Co-Leader, Thoracic Cancer Service Line
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Genmab, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Lilly; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck.

    Leena Gandhi, MD, PhD
    Director, Perlmutter Cancer Center
    Langone Health
    New York University
    New York, New York

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Ignyta Inc, Merck, Syndax Pharmaceuticals Inc.

    Matthew D Hellmann, MD
    Medical Oncologist
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Janssen Biotech Inc, Merck, Novartis.

    Roy S Herbst, MD, PhD
    Ensign Professor of Medicine
    Professor of Pharmacology
    Chief of Medical Oncology
    Director, Thoracic Oncology Research Program
    Associate Director for Translational Research
    Yale Comprehensive Cancer Center
    Yale School of Medicine
    New Haven, Connecticut

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Lilly, Merck, Pfizer Inc; Contracted Research: Genentech BioOncology, Merck.

    Corey J Langer, MD
    Director of Thoracic Oncology
    Abramson Cancer Center
    Professor of Medicine
    Perelman School of Medicine
    University of Pennsylvania
    Vice Chair, Radiation Therapy Oncology Group
    Philadelphia, Pennsylvania

    Advisory Committee: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Genentech BioOncology, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Ariad Pharmaceuticals Inc, GlaxoSmithKline, Inovio Pharmaceuticals Inc, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc.

    Audience Engagement Liaison

    Matthew Gubens, MD, MS
    Associate Professor, Thoracic Medical Oncology
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Mersana Therapeutics, Novartis; Contracted Research: Celgene Corporation, Merck, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: June 2018
    Expiration date: June 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):